Daniel O'Day, Gilead CEO (Andrew Harnik/AP Images)

Gilead to snap up liv­er dis­ease biotech CymaBay for $4.3B

Gilead is bet­ting $4.3 bil­lion on a biotech six months be­fore the FDA is ex­pect­ed to make an ap­proval de­ci­sion on its rare liv­er dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.